Welcome to our dedicated page for Cresco Labs SEC filings (Ticker: CRLBF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cresco Labs Inc. (CRLBF) SEC filings page brings together the company’s regulatory disclosures as a foreign private issuer. Cresco Labs files annual reports on Form 40-F and furnishes Form 6-K current reports that include interim financial statements, management’s discussion and analysis, and key corporate documents. These filings offer detailed insight into its cannabis cultivation, production, branded product distribution and Sunnyside retail operations.
Investors can use Cresco Labs’ filings to review unaudited condensed interim consolidated financial statements for specific quarters, along with accompanying MD&A that discusses financial condition, results of operations and risk factors. The company also uses Form 6-K to file materials such as senior secured term loan agreements and related news releases, which explain the terms of its credit facilities, refinancing transactions, interest rates and maturity profiles.
Through its SEC submissions, Cresco Labs discloses both U.S. GAAP results and non-GAAP financial measures, including EBITDA, Adjusted EBITDA, Adjusted gross profit and associated margins. Reconciliations in these documents help readers understand how management evaluates core operating performance relative to reported figures.
On this page, Stock Titan provides real-time access to new Cresco Labs filings as they appear on EDGAR, along with AI-powered summaries that highlight the main points of lengthy documents. Users can quickly locate quarterly updates, annual 40-F reports, financing agreements and other material disclosures without reading every line of the original text. For those tracking CRLBF, this centralized view of SEC filings supports analysis of profitability trends, capital structure decisions and the regulatory reporting history of Cresco Labs’ cannabis business.
Cresco Labs Inc. has launched an at-the-market equity program qualifying for distribution of up to C$140,000,000 of Subordinate Voting Shares through Haywood Securities as agent. Shares will be sold on the CSE and other Canadian marketplaces at prevailing market prices, with no minimum raise.
The company will pay the agent a 2.5% commission on gross proceeds and estimates offering expenses of about US$250,000. Net proceeds are intended for general corporate purposes, debt repayment, capital programs and potential acquisitions, and may be used to support periods of negative operating cash flow. As of September 30, 2025, Cresco had 340,486,810 Subordinate Voting Shares outstanding, so actual dilution will depend on how much of the facility is used.
Cresco Labs Inc. has completed its previously announced employee option exchange offer. Shareholder approval for the Exchange Offer was obtained at the annual general and special meeting held on September 16, 2025, and the offer expired at 11:59 p.m. Eastern Time on September 17, 2025.
A total of 14 eligible participants elected to exchange options to purchase an aggregate of 8,865,902 subordinate voting shares, which the company accepted for cancellation. These options represented approximately 99% of the subordinate voting shares underlying Eligible Options. Immediately after expiration of the Exchange Offer on September 17, 2025, the company granted 8,865,902 restricted stock units (RSUs) under its 2018 Incentive Plan. The new RSU awards vest ratably over three years as described in the Exchange Offer.